Business Context and Reporting Period
The Chemours Company (CC) filed a Form 8-K on March 26, 2024. This filing serves as a Regulation FD disclosure to announce the upcoming release of financial results for the fourth quarter and full year ended December 31, 2023.
Key Financial Metrics
This filing does not contain specific financial data. Revenue, profit, cash flow, margins, debt, and liquidity figures for the reported period are not included in this document; they are scheduled for release in the upcoming Form 10-K and press release.
Material Changes
No material changes to financial performance or operations are detailed in this filing. The document solely addresses the timing of the upcoming earnings announcement.
Guidance, Outlook, and Management Commentary
Management has announced the following schedule for the release of 2023 financial results:
- Results Release: After market close on Wednesday, March 27, 2024.
- Conference Call: 8:00 a.m. Eastern Daylight Time on Thursday, March 28, 2024.
The filing explicitly states that the information provided, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the exact time of the earnings release on March 27, 2024, to ensure access to the Form 10-K and press release.
- Confirm the dial-in details for the conference call scheduled for March 28, 2024, via the attached Exhibit 99.1.
- Note that Matthew S. Abbott is signing as Interim Chief Financial Officer.